Cargando…
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
BACKGROUND: Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluated the efficacy of two different doses of weekly nab-paclitaxel, with a specific...
Autores principales: | Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, McCartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, De Placido, Sabino, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, Mottino, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405344/ https://www.ncbi.nlm.nih.gov/pubmed/32758299 http://dx.doi.org/10.1186/s13058-020-01319-1 |
Ejemplares similares
-
The best treatment for older patients with breast cancer
por: Turner, Natalie, et al.
Publicado: (2013) -
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018) -
The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018) -
Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer
por: Vignoli, Alessia, et al.
Publicado: (2021) -
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
por: Rossi, Lorenzo, et al.
Publicado: (2019)